Search

Displaying results 4931 - 4940 of 6835 in total
  1. Drug

    Canertinib

    go.drugbank.com/drugs/DB05424
    Investigational

    Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

  2. Drug

    Pegilodecakin

    go.drugbank.com/drugs/DB15162
    Investigational

    Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small

  3. Drug

    DDP-225

    go.drugbank.com/drugs/DB05642
    Investigational

    Dynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Pharma in October 2003. … Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system.

  4. Drug

    Benzoylecgonine

    go.drugbank.com/drugs/DB01515
    ExperimentalIllicit

    It is formed by hydrolysis of cocaine in the liver, catalysed by carboxylesterases. It is excreted in the urine of cocaine users after processing in the liver.

    Synonyms: O-benzoylecgonine, O-benzoyl-(-)-ecgonine
  5. Drug

    AGT-182

    go.drugbank.com/drugs/DB17630
    Investigational

    AGT-182 is an investigational enzyme replacement therapy engineered by the fusion of the iduronate-2-sulfatase (IDS) enzyme and a human insulin receptor monoclonal antibody.

  6. Drug

    TAK-611

    go.drugbank.com/drugs/DB17644
    Investigational

    First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.

  7. Drug

    Tavapadon

    go.drugbank.com/drugs/DB14899
    Investigational

    Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride

  8. Drug

    Sulbutiamine

    go.drugbank.com/drugs/DB13416
    Investigational

    Sulbutiamine is a synthetic derivative of thiamine (vitamin B1) under the market name Arcalion that is composed of two modified thiamine molecules to form a dimer. … Although its clinical efficacy is not yet defined, sulbutiamine is used to treat asthenia.

  9. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    Similar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer … a greater affinity for free serum IgE and an altered sensitivity to IgE conformation.

  10. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. … This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.